25 XP   0   0   10

Shanghai Kaibao Pharmaceutical
Buy, Hold or Sell?

Let's analyse Shanghai Kaibao Pharmaceutical together

PenkeI guess you are interested in Shanghai Kaibao Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Shanghai Kaibao Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Shanghai Kaibao Pharmaceutical

I send you an email if I find something interesting about Shanghai Kaibao Pharmaceutical.

Quick analysis of Shanghai Kaibao Pharmaceutical (30 sec.)










What can you expect buying and holding a share of Shanghai Kaibao Pharmaceutical? (30 sec.)

How much money do you get?

How much money do you get?
¥0.03
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥3.60
Expected worth in 1 year
¥6.33
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
¥2.94
Return On Investment
50.4%

For what price can you sell your share?

Current Price per Share
¥5.83
Expected price per share
¥5.25 - ¥6.18
How sure are you?
50%

1. Valuation of Shanghai Kaibao Pharmaceutical (5 min.)




Live pricePrice per Share (EOD)

¥5.83

Intrinsic Value Per Share

¥1.87 - ¥3.29

Total Value Per Share

¥5.46 - ¥6.89

2. Growth of Shanghai Kaibao Pharmaceutical (5 min.)




Is Shanghai Kaibao Pharmaceutical growing?

Current yearPrevious yearGrowGrow %
How rich?$519.7m$420.8m$98.9m19.0%

How much money is Shanghai Kaibao Pharmaceutical making?

Current yearPrevious yearGrowGrow %
Making money$26.3m$19.3m$7m26.6%
Net Profit Margin17.1%12.7%--

How much money comes from the company's main activities?

3. Financial Health of Shanghai Kaibao Pharmaceutical (5 min.)




What can you expect buying and holding a share of Shanghai Kaibao Pharmaceutical? (5 min.)

Welcome investor! Shanghai Kaibao Pharmaceutical's management wants to use your money to grow the business. In return you get a share of Shanghai Kaibao Pharmaceutical.

What can you expect buying and holding a share of Shanghai Kaibao Pharmaceutical?

First you should know what it really means to hold a share of Shanghai Kaibao Pharmaceutical. And how you can make/lose money.

Speculation

The Price per Share of Shanghai Kaibao Pharmaceutical is ¥5.83. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Shanghai Kaibao Pharmaceutical.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Shanghai Kaibao Pharmaceutical, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥3.60. Based on the TTM, the Book Value Change Per Share is ¥0.68 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.05 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Shanghai Kaibao Pharmaceutical.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.030.4%0.030.4%0.020.3%0.020.4%0.030.5%
Usd Book Value Change Per Share0.091.6%0.091.6%0.061.1%0.040.7%0.030.5%
Usd Dividend Per Share0.010.1%0.010.1%0.000.1%0.010.2%0.010.2%
Usd Total Gains Per Share0.101.7%0.101.7%0.071.1%0.050.8%0.040.8%
Usd Price Per Share1.11-1.11-0.85-0.78-1.19-
Price to Earnings Ratio44.19-44.19-45.99-35.65-37.85-
Price-to-Total Gains Ratio10.97-10.97-12.93-21.79-31.68-
Price to Book Ratio2.24-2.24-2.12-2.02-4.16-
Price-to-Total Gains Ratio10.97-10.97-12.93-21.79-31.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.805706
Number of shares1241
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.090.04
Usd Total Gains Per Share0.100.05
Gains per Quarter (1241 shares)125.9960.71
Gains per Year (1241 shares)503.97242.85
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
13447049452190233
269939998105381476
310314091502157571719
413718792006210762962
5172234825102629521205
62062818301431411431448
72403288351836713331691
82743757402241915241934
93094227452647217142177
103434697503052419042420

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%17.00.00.0100.0%

Fundamentals of Shanghai Kaibao Pharmaceutical

About Shanghai Kaibao Pharmaceutical

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongdan dropping pills that clears heat, calms liver, and improves eyesight. The company was founded in 2000 and is based in Shanghai, China.

Fundamental data was last updated by Penke on 2024-04-16 11:37:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of Shanghai Kaibao Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Shanghai Kaibao Pharmaceutical earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 17.1% means that ¥0.17 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 17.1%. The company is making a huge profit. +2
  • The TTM is 17.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ17.1%TTM17.1%0.0%
TTM17.1%YOY12.7%+4.3%
TTM17.1%5Y14.9%+2.2%
5Y14.9%10Y17.8%-3.0%
1.1.2. Return on Assets

Shows how efficient Shanghai Kaibao Pharmaceutical is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.5% Return on Assets means that Shanghai Kaibao Pharmaceutical generated ¥0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 4.5%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.5%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.5%TTM4.5%0.0%
TTM4.5%YOY4.2%+0.3%
TTM4.5%5Y5.9%-1.4%
5Y5.9%10Y9.7%-3.8%
1.1.3. Return on Equity

Shows how efficient Shanghai Kaibao Pharmaceutical is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • 5.1% Return on Equity means Shanghai Kaibao Pharmaceutical generated ¥0.05 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 5.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 5.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.1%TTM5.1%0.0%
TTM5.1%YOY4.6%+0.5%
TTM5.1%5Y6.5%-1.5%
5Y6.5%10Y10.9%-4.4%

1.2. Operating Efficiency of Shanghai Kaibao Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Shanghai Kaibao Pharmaceutical is operating .

  • Measures how much profit Shanghai Kaibao Pharmaceutical makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY10.8%-10.8%
TTM-5Y11.8%-11.8%
5Y11.8%10Y12.6%-0.8%
1.2.2. Operating Ratio

Measures how efficient Shanghai Kaibao Pharmaceutical is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.04 means that the operating costs are ¥1.04 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 1.039. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.039. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.039TTM1.0390.000
TTM1.039YOY1.092-0.054
TTM1.0395Y1.035+0.004
5Y1.03510Y0.836+0.198

1.3. Liquidity of Shanghai Kaibao Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Shanghai Kaibao Pharmaceutical is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 5.32 means the company has ¥5.32 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 5.320. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.320. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.320TTM5.3200.000
TTM5.320YOY11.823-6.503
TTM5.3205Y9.021-3.701
5Y9.02110Y6.444+2.577
1.3.2. Quick Ratio

Measures if Shanghai Kaibao Pharmaceutical is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.73 means the company can pay off ¥1.73 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 1.726. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.726. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.726TTM1.7260.000
TTM1.726YOY3.493-1.767
TTM1.7265Y3.116-1.390
5Y3.11610Y2.955+0.161

1.4. Solvency of Shanghai Kaibao Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Shanghai Kaibao Pharmaceutical assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Shanghai Kaibao Pharmaceutical to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.12 means that Shanghai Kaibao Pharmaceutical assets are financed with 11.7% credit (debt) and the remaining percentage (100% - 11.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 0.117. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.117. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.117TTM0.1170.000
TTM0.117YOY0.093+0.024
TTM0.1175Y0.101+0.016
5Y0.10110Y0.113-0.012
1.4.2. Debt to Equity Ratio

Measures if Shanghai Kaibao Pharmaceutical is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 13.2% means that company has ¥0.13 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The MRQ is 0.132. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.132. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.132TTM0.1320.000
TTM0.132YOY0.102+0.030
TTM0.1325Y0.112+0.020
5Y0.11210Y0.128-0.016

2. Market Valuation of Shanghai Kaibao Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Shanghai Kaibao Pharmaceutical generates.

  • Above 15 is considered overpriced but always compare Shanghai Kaibao Pharmaceutical to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 44.19 means the investor is paying ¥44.19 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The EOD is 31.960. Based on the earnings, the company is overpriced. -1
  • The MRQ is 44.185. Based on the earnings, the company is overpriced. -1
  • The TTM is 44.185. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD31.960MRQ44.185-12.225
MRQ44.185TTM44.1850.000
TTM44.185YOY45.987-1.801
TTM44.1855Y35.647+8.539
5Y35.64710Y37.846-2.200
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The EOD is 17.686. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 24.451. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is 24.451. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD17.686MRQ24.451-6.765
MRQ24.451TTM24.4510.000
TTM24.451YOY77.138-52.687
TTM24.4515Y31.593-7.142
5Y31.59310Y44.480-12.887
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Shanghai Kaibao Pharmaceutical is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Shanghai Kaibao Pharmaceutical:

  • The EOD is 1.621. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.242. Based on the equity, the company is underpriced. +1
  • The TTM is 2.242. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.621MRQ2.242-0.620
MRQ2.242TTM2.2420.000
TTM2.242YOY2.116+0.126
TTM2.2425Y2.025+0.217
5Y2.02510Y4.164-2.140
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Shanghai Kaibao Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6850.6850%0.446+53%0.278+147%0.224+206%
Book Value Per Share--3.5963.5960%2.911+24%2.749+31%2.331+54%
Current Ratio--5.3205.3200%11.823-55%9.021-41%6.444-17%
Debt To Asset Ratio--0.1170.1170%0.093+26%0.101+16%0.113+4%
Debt To Equity Ratio--0.1320.1320%0.102+30%0.112+18%0.128+3%
Dividend Per Share--0.0500.0500%0.030+65%0.076-35%0.094-47%
Eps--0.1820.1820%0.134+36%0.174+5%0.230-21%
Free Cash Flow Per Share--0.3300.3300%0.080+313%0.232+42%0.223+48%
Free Cash Flow To Equity Per Share--0.3300.3300%0.014+2335%0.140+136%0.143+131%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--3.292--------
Intrinsic Value_10Y_min--1.868--------
Intrinsic Value_1Y_max--0.254--------
Intrinsic Value_1Y_min--0.208--------
Intrinsic Value_3Y_max--0.821--------
Intrinsic Value_3Y_min--0.610--------
Intrinsic Value_5Y_max--1.457--------
Intrinsic Value_5Y_min--0.994--------
Market Cap6098180000.000-38%8430760000.0008430760000.0000%6443360000.000+31%5911772965.600+43%9010658539.600-6%
Net Profit Margin--0.1710.1710%0.127+34%0.149+15%0.178-4%
Operating Margin----0%0.108-100%0.118-100%0.126-100%
Operating Ratio--1.0391.0390%1.092-5%1.035+0%0.836+24%
Pb Ratio1.621-38%2.2422.2420%2.116+6%2.025+11%4.164-46%
Pe Ratio31.960-38%44.18544.1850%45.987-4%35.647+24%37.846+17%
Price Per Share5.830-38%8.0608.0600%6.160+31%5.632+43%8.589-6%
Price To Free Cash Flow Ratio17.686-38%24.45124.4510%77.138-68%31.593-23%44.480-45%
Price To Total Gains Ratio7.936-38%10.97210.9720%12.932-15%21.792-50%31.679-65%
Quick Ratio--1.7261.7260%3.493-51%3.116-45%2.955-42%
Return On Assets--0.0450.0450%0.042+7%0.059-24%0.097-54%
Return On Equity--0.0510.0510%0.046+10%0.065-22%0.109-54%
Total Gains Per Share--0.7350.7350%0.476+54%0.354+108%0.318+131%
Usd Book Value--519774453.192519774453.1920%420806813.404+24%399090853.523+30%338602597.416+54%
Usd Book Value Change Per Share--0.0950.0950%0.062+53%0.038+147%0.031+206%
Usd Book Value Per Share--0.4970.4970%0.402+24%0.380+31%0.322+54%
Usd Dividend Per Share--0.0070.0070%0.004+65%0.011-35%0.013-47%
Usd Eps--0.0250.0250%0.019+36%0.024+5%0.032-21%
Usd Free Cash Flow--47651626.77347651626.7730%11543880.886+313%33719730.446+41%32429941.323+47%
Usd Free Cash Flow Per Share--0.0460.0460%0.011+313%0.032+42%0.031+48%
Usd Free Cash Flow To Equity Per Share--0.0460.0460%0.002+2335%0.019+136%0.020+131%
Usd Market Cap842768476.000-38%1165131032.0001165131032.0000%890472352.000+31%817007023.846+43%1245273010.173-6%
Usd Price Per Share0.806-38%1.1141.1140%0.851+31%0.778+43%1.187-6%
Usd Profit--26369182.94226369182.9420%19363703.034+36%25286171.211+4%33438413.264-21%
Usd Revenue--154625142.588154625142.5880%152099933.683+2%167142960.754-7%183990002.650-16%
Usd Total Gains Per Share--0.1020.1020%0.066+54%0.049+108%0.044+131%
 EOD+4 -4MRQTTM+0 -0YOY+27 -85Y+20 -1510Y+15 -20

3.2. Fundamental Score

Let's check the fundamental score of Shanghai Kaibao Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1531.960
Price to Book Ratio (EOD)Between0-11.621
Net Profit Margin (MRQ)Greater than00.171
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.726
Current Ratio (MRQ)Greater than15.320
Debt to Asset Ratio (MRQ)Less than10.117
Debt to Equity Ratio (MRQ)Less than10.132
Return on Equity (MRQ)Greater than0.150.051
Return on Assets (MRQ)Greater than0.050.045
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Shanghai Kaibao Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.196
Ma 20Greater thanMa 506.103
Ma 50Greater thanMa 1006.167
Ma 100Greater thanMa 2006.444
OpenGreater thanClose5.650
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets4,259,271
Total Liabilities498,241
Total Stockholder Equity3,761,753
 As reported
Total Liabilities 498,241
Total Stockholder Equity+ 3,761,753
Total Assets = 4,259,271

Assets

Total Assets4,259,271
Total Current Assets1,574,429
Long-term Assets2,684,842
Total Current Assets
Cash And Cash Equivalents 694,690
Short-term Investments 136,075
Net Receivables 374,675
Inventory 160,800
Other Current Assets 3,841
Total Current Assets  (as reported)1,574,429
Total Current Assets  (calculated)1,370,081
+/- 204,349
Long-term Assets
Property Plant Equipment 304,663
Goodwill 9,040
Intangible Assets 44,228
Long-term Assets Other 996,495
Long-term Assets  (as reported)2,684,842
Long-term Assets  (calculated)1,354,427
+/- 1,330,415

Liabilities & Shareholders' Equity

Total Current Liabilities295,959
Long-term Liabilities202,282
Total Stockholder Equity3,761,753
Total Current Liabilities
Accounts payable 91,011
Other Current Liabilities 12,236
Total Current Liabilities  (as reported)295,959
Total Current Liabilities  (calculated)103,246
+/- 192,713
Long-term Liabilities
Long-term Liabilities  (as reported)202,282
Long-term Liabilities  (calculated)0
+/- 202,282
Total Stockholder Equity
Retained Earnings 1,567,755
Total Stockholder Equity (as reported)3,761,753
Total Stockholder Equity (calculated)1,567,755
+/- 2,193,998
Other
Capital Stock1,046,000
Common Stock Shares Outstanding 1,046,000
Net Invested Capital 3,761,753
Net Working Capital 1,278,470
Property Plant and Equipment Gross 806,330



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-31
> Total Assets 
109,035
161,606
229,875
1,345,390
1,370,399
1,452,404
1,561,085
1,770,810
2,117,367
2,426,669
2,527,916
2,679,724
2,747,389
2,842,499
2,877,284
3,355,817
4,259,271
4,259,2713,355,8172,877,2842,842,4992,747,3892,679,7242,527,9162,426,6692,117,3671,770,8101,561,0851,452,4041,370,3991,345,390229,875161,606109,035
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
1,917,842
1,922,946
2,101,542
2,159,600
2,263,680
2,219,863
2,254,418
1,574,429
1,574,4292,254,4182,219,8632,263,6802,159,6002,101,5421,922,9461,917,842000000000
       Cash And Cash Equivalents 
5,741
11,312
29,907
1,014,055
832,913
796,970
841,682
814,013
816,632
902,393
701,620
581,999
547,054
809,523
1,307,082
1,344,949
694,690
694,6901,344,9491,307,082809,523547,054581,999701,620902,393816,632814,013841,682796,970832,9131,014,05529,90711,3125,741
       Short-term Investments 
0
0
0
0
0
0
0
0
190,000
100,000
41,578
103,381
84,281
485,566
114,647
51,262
136,075
136,07551,262114,647485,56684,281103,38141,578100,000190,00000000000
       Net Receivables 
61,863
89,873
111,271
121,653
205,777
322,262
346,416
427,316
540,195
685,442
639,439
745,599
740,543
721,066
319,556
614,760
374,675
374,675614,760319,556721,066740,543745,599639,439685,442540,195427,316346,416322,262205,777121,653111,27189,87361,863
       Other Current Assets 
802
2,915
16,102
26,741
55,019
38,673
70,804
70,443
64,325
27,364
15,010
28,786
614,371
3,818
8,081
19,990
3,841
3,84119,9908,0813,818614,37128,78615,01027,36464,32570,44370,80438,67355,01926,74116,1022,915802
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
604,970
578,182
587,788
578,819
657,422
1,101,399
2,684,842
2,684,8421,101,399657,422578,819587,788578,182604,9700000000000
       Property Plant Equipment 
30,545
31,325
34,446
148,437
214,895
251,224
252,519
355,655
347,188
401,089
372,849
374,385
353,288
326,810
295,866
307,782
304,663
304,663307,782295,866326,810353,288374,385372,849401,089347,188355,655252,519251,224214,895148,43734,44631,32530,545
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18,500
13,794
9,040
9,04013,79418,50000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
55,800
180,825
154,345
182,436
0
0
0
0
0000182,436154,345180,82555,800000000000
       Intangible Assets 
1,323
966
3,322
25
25
0
0
0
47,123
46,793
45,379
43,749
42,120
41,333
45,263
42,903
44,228
44,22842,90345,26341,33342,12043,74945,37946,79347,12300025253,3229661,323
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
604,970
578,182
587,788
10,553
20,446
10,755
996,495
996,49510,75520,44610,553587,788578,182604,9700000000000
> Total Liabilities 
71,799
84,644
102,951
199,200
133,388
117,974
142,286
164,717
232,722
421,159
327,605
314,258
262,260
273,008
298,960
310,905
498,241
498,241310,905298,960273,008262,260314,258327,605421,159232,722164,717142,286117,974133,388199,200102,95184,64471,799
   > Total Current Liabilities 
71,799
84,644
102,951
186,200
118,568
103,364
118,750
142,202
211,018
375,759
286,567
279,468
235,154
240,024
237,547
190,680
295,959
295,959190,680237,547240,024235,154279,468286,567375,759211,018142,202118,750103,364118,568186,200102,95184,64471,799
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,723
0
0
0035,72300000000000000
       Accounts payable 
17,251
2,886
6,764
8,230
32,182
14,996
18,523
18,670
38,630
87,259
60,741
60,874
64,250
77,926
62,229
75,016
91,011
91,01175,01662,22977,92664,25060,87460,74187,25938,63018,67018,52314,99632,1828,2306,7642,88617,251
       Other Current Liabilities 
48,048
81,758
76,887
59,470
86,386
88,368
100,227
123,532
172,389
262,347
215,813
171,066
143,881
140,948
126,126
99,744
12,236
12,23699,744126,126140,948143,881171,066215,813262,347172,389123,532100,22788,36886,38659,47076,88781,75848,048
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
41,038
34,790
27,105
32,984
61,413
120,225
202,282
202,282120,22561,41332,98427,10534,79041,0380000000000
       Other Liabilities 
0
0
0
13,000
14,820
14,610
23,536
22,515
21,703
45,400
41,038
34,790
27,105
32,984
61,413
120,225
0
0120,22561,41332,98427,10534,79041,03845,40021,70322,51523,53614,61014,82013,000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
1,260
981
725
469
213
0
0
0
0002134697259811,260000000000
> Total Stockholder Equity
37,236
75,082
126,924
1,146,191
1,237,011
1,334,430
1,418,798
1,606,093
1,884,645
2,005,509
2,200,311
2,365,466
2,485,129
2,569,492
2,578,324
3,044,914
3,761,753
3,761,7533,044,9142,578,3242,569,4922,485,1292,365,4662,200,3112,005,5091,884,6451,606,0931,418,7981,334,4301,237,0111,146,191126,92475,08237,236
   Common Stock
12,000
12,000
82,200
109,600
175,360
263,040
263,040
526,080
640,376
833,685
829,432
1,071,494
1,071,494
1,046,000
1,046,000
1,046,000
0
01,046,0001,046,0001,046,0001,071,4941,071,494829,432833,685640,376526,080263,040263,040175,360109,60082,20012,00012,000
   Retained Earnings 
21,704
55,099
27,946
65,016
143,390
224,320
284,468
439,882
750,779
950,811
1,150,984
1,285,348
1,405,011
1,466,502
1,468,025
1,576,759
1,567,755
1,567,7551,576,7591,468,0251,466,5021,405,0111,285,3481,150,984950,811750,779439,882284,468224,320143,39065,01627,94655,09921,704
   Capital Surplus 00000000000000000
   Treasury Stock000000-29,830-55,367000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
48,365
55,675
413,531
0
0413,53155,67548,3650000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,473,166
Cost of Revenue-316,166
Gross Profit1,157,0001,157,000
 
Operating Income (+$)
Gross Profit1,157,000
Operating Expense-1,185,524
Operating Income287,642-28,524
 
Operating Expense (+$)
Research Development93,603
Selling General Administrative726,505
Selling And Marketing Expenses-
Operating Expense1,185,524820,108
 
Net Interest Income (+$)
Interest Income41,929
Interest Expense--
Other Finance Cost-1,340
Net Interest Income43,269
 
Pretax Income (+$)
Operating Income287,642
Net Interest Income43,269
Other Non-Operating Income Expenses-
Income Before Tax (EBT)321,112287,642
EBIT - interestExpense = 0
268,316
268,316
Interest Expense-
Earnings Before Interest and Taxes (EBIT)-321,112
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax321,112
Tax Provision-53,240
Net Income From Continuing Ops267,872267,872
Net Income268,316
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--43,269
 

Technical Analysis of Shanghai Kaibao Pharmaceutical
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Shanghai Kaibao Pharmaceutical. The general trend of Shanghai Kaibao Pharmaceutical is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Shanghai Kaibao Pharmaceutical's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Shanghai Kaibao Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5.95 < 6.18 < 6.18.

The bearish price targets are: 5.46 > 5.2892 > 5.25.

Tweet this
Shanghai Kaibao Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Shanghai Kaibao Pharmaceutical. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shanghai Kaibao Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Shanghai Kaibao Pharmaceutical. The current macd is -0.1341485.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Shanghai Kaibao Pharmaceutical price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Shanghai Kaibao Pharmaceutical. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Shanghai Kaibao Pharmaceutical price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Shanghai Kaibao Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartShanghai Kaibao Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Shanghai Kaibao Pharmaceutical. The current adx is 19.62.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Shanghai Kaibao Pharmaceutical shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Shanghai Kaibao Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Shanghai Kaibao Pharmaceutical. The current sar is 6.09308108.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Shanghai Kaibao Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Shanghai Kaibao Pharmaceutical. The current rsi is 41.20. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Shanghai Kaibao Pharmaceutical Daily Relative Strength Index (RSI) ChartShanghai Kaibao Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Shanghai Kaibao Pharmaceutical. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Shanghai Kaibao Pharmaceutical price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Shanghai Kaibao Pharmaceutical Daily Stochastic Oscillator ChartShanghai Kaibao Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Shanghai Kaibao Pharmaceutical. The current cci is -133.39774557.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Shanghai Kaibao Pharmaceutical Daily Commodity Channel Index (CCI) ChartShanghai Kaibao Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Shanghai Kaibao Pharmaceutical. The current cmo is -18.58146846.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Shanghai Kaibao Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartShanghai Kaibao Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Shanghai Kaibao Pharmaceutical. The current willr is -64.78873239.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Shanghai Kaibao Pharmaceutical is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Shanghai Kaibao Pharmaceutical Daily Williams %R ChartShanghai Kaibao Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Shanghai Kaibao Pharmaceutical.

Shanghai Kaibao Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Shanghai Kaibao Pharmaceutical. The current atr is 0.18868455.

Shanghai Kaibao Pharmaceutical Daily Average True Range (ATR) ChartShanghai Kaibao Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Shanghai Kaibao Pharmaceutical. The current obv is 1,400,881,160.

Shanghai Kaibao Pharmaceutical Daily On-Balance Volume (OBV) ChartShanghai Kaibao Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Shanghai Kaibao Pharmaceutical. The current mfi is 37.56.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Shanghai Kaibao Pharmaceutical Daily Money Flow Index (MFI) ChartShanghai Kaibao Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Shanghai Kaibao Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-24ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-26BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Shanghai Kaibao Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Shanghai Kaibao Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.196
Ma 20Greater thanMa 506.103
Ma 50Greater thanMa 1006.167
Ma 100Greater thanMa 2006.444
OpenGreater thanClose5.650
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Shanghai Kaibao Pharmaceutical with someone you think should read this too:
  • Are you bullish or bearish on Shanghai Kaibao Pharmaceutical? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Shanghai Kaibao Pharmaceutical? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Shanghai Kaibao Pharmaceutical

I send you an email if I find something interesting about Shanghai Kaibao Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Shanghai Kaibao Pharmaceutical.

Receive notifications about Shanghai Kaibao Pharmaceutical in your mailbox!